BioCryst Pharma (BCRX) Tops Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.29 +1.98%
EPS Growth %: +6.7%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
UBAB, LOAN, FITB, More
EPS Growth %: +6.7%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $71.47 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
- VIST Financial Corp. (VIST) Misses Q2 EPS by 76c
- Cohen & Steers (CNS) Tops Q2 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
